Eisai
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eisai sits in the top decile of US sponsors by registered trial count (#121 of 15,742 sponsors by registered trial count).
Eisai: 287 sponsored US clinical trials, 5 recruiting.
Eisai sponsors 287 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 243 completed. 67 of these trials are in Phase 3-4 (later-stage) and 214 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Subjects, with 6 trials.
Top-decile sponsor footprint
Eisai ranks in the top decile of sponsors by registered trial count (#121 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
243 of 273 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
287 total, page 1 of 6
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
NCT07493265
A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants
NCT07308236
A Study of Oral E1018 in Healthy Adult Participants
NCT06854042
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
NCT04015141
A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population
NCT06744673
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
NCT06602258
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
NCT06188559
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
NCT04288089
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455
Study of E7386 in Participants With Selected Advanced Neoplasms
NCT03264664
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861
A Study of E2086 in Healthy Adult Participants
NCT06481488
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
NCT06462404
A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants
NCT05745207
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants
NCT05726851
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
NCT05533801
A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants
NCT05147337
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
NCT05091346
A Study of Subcutaneous Lecanemab in Healthy Participants
NCT05045716
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
NCT04971733
A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women
NCT04890561
A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma
NCT04763408
A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
NCT04764669
A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT04647383
A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy Participants
NCT04676685
A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
NCT04572243
A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants
NCT04547361
A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm Disorder
NCT04300569
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
NCT04154189
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
NCT04144140
A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants
NCT04231513
A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants
NCT04023877
A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia
NCT04009577
A Food-Effect Study of E7386 in Healthy Participants
NCT03996226
A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy
NCT03686033
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
NCT03477175
A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants
NCT03627936
A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy
NCT03603639
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
NCT03517449
Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies
NCT03467152
Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
NCT03433703
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
NCT03441360
Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea
NCT03471871
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Participants
NCT03451890
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment
NCT03443063
Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects
NCT03451110
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
NCT03440424
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 122 |
| Phase 2 | 92 |
| Phase 3 | 52 |
| Phase 4 | 15 |
Therapeutic Areas
What is open in the Eisai pipeline
5 recruiting of 287 indexed (2% open); 243 completed (85%).
Phase mix: 67 late (III/IV) vs 214 early (I/II) (early-phase heavy).
Top condition: Healthy Subjects (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eisai: open-pipeline peers nationwide
Peers matched on 287 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Eisai sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 287 trials (± recruiting share)
- University of Missouri-Columbia · 291 trials · 19% recruiting
- Thomas Jefferson University · 292 trials · 18% recruiting
- University of Michigan Rogel Cancer Center · 292 trials · 15% recruiting
- Kaiser Permanente · 294 trials · 7% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Medtronic Cardiac Rhythm and Heart Failure · 2% recruiting · 115 trials
- Bausch & Lomb Incorporated · 2% recruiting · 174 trials
- Lexicon Pharmaceuticals · 2% recruiting · 56 trials
- Alcon Research · 2% recruiting · 275 trials
Related
What to do with this Eisai page
287 registered trials is a research-attention snapshot, not an endorsement of Eisai or any single study.
- 5 of Eisai's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy Subjects is the condition Eisai studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Subjects trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Eisai pipeline card: 287 registered trials from official public datasets.Report a data error.